+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-11-14Number of Pages: 170

Rare Hematology Market (Product Type - Plasma Derived Factors, Recombinant Factors, Hemophilia A, Hemophilia B, Von Wilebrand Disease, Acquired Hemophilia A, Others; Age -Adult and Pediatric) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022

Growing prevalence of various blood diseases such as anemia, myeloma, leukemia and sickle cell anemia has led the hematologists to focus on various detection processes. As demand for comparatively conducting comparatively short diagnosis process is becoming the need of the hour, hematologists are looking for better treatment processes through accurate diagnosis process. With the growing need to detect various blood conditions has further propelled hematologists to focus on enhancing their diagnostic skills. In order to develop successful treatment techniques, hematologist are significantly focusing on early diagnosis of the various hematologist diseases. Bound to these factors, growth of the global hematologist disease treatment market will continue to gain momentum during the forecast period.

According to Transparency Market Research, the global rare hematology market is expected to represent a value of over US$ 16,000 Mn by the end of 2022.

rare hematology market

Market Taxonomy

Region

Treatment Type

Indication

Age Group

North America

Plasma Derived Factors

Hemophilia A

Adult (18+)

Latin America

Recombinant Factors

Hemophilia B

Pediatric (0-17)

Europe

 

Von Wilebrand Disease

 

Japan

 

Acquired Hemophilia A

 

APEJ

 

Others

 

MEA

 

 

 

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Increasing number of Clinical Trials to Encourage Progress

Hematologists are conducting extensive research for genetics and molecular biology in order to gain a better understanding of various rare hematology diseases. The research work is mainly conducted in order to identify the potential biological targets that help in addressing the diseases on the molecular level. The extensive research work has enabled the hematologists to develop the new treatment techniques that enable faster recovery. Hundreds of the final stage clinical trials are stuck in the FDA pipeline to be evaluated and approved. Treatment procedures related to rare hematology diseases include recombinant coagulation Factor VIIa, Eculizumab: hemoglobinuria, Poloxamer 188: sickle cell disease and nonacog beta pegol: hemophilia A & B. Advocacy groups such as International National Hemophilia Foundation, Myeloma Foundation and American Society of Hematology further continue to offer resources and support for the caregivers, patients and clinicians. Bound to these factors, demand for the rare hematology will continue to increase globally.

Inadequate Hematology Data to Inhibit Market Growth

Lack of support from disease-specific foundations for the purpose of research has continued to inhibit growth of the global rare hematology market during the forecast period. According to Kakkis EverLife foundations, majority of the drugs finalized for the treatment of the various rare hematology disorders did not clear the FDA pipeline for treatment. Increasing demand for approved drugs for the treatment of the rare hematology disorders has led to increasing investments in research and development to develop better treatment process. Bound to various factors including the political, social and economic situations, majority of the patient population have been subject to improper management of treatment and their conditions.

Advocacy groups, patients, caregivers and researchers are coming together in order to spread awareness regarding various blood related diseases. Moreover, the drug developers are increasingly benefitting by pool of specific patients as it enabled the identified patient group to register into the clinical trials. Research related to various rare hematology diseases continues to gain momentum in developed countries such as the U.S. The House of Representatives in the U.S passed the 21st Century Cures Act in 2016, which is focused towards integrating the opinions of the patients that would help in designing the clinical trials related to these diseases. Such factors are expected to contribute towards growth of the global rare hematology market.

Adult Age to Represent a Leading Segment

With growing prevalence of blood disorders and bleeding, demand for the recombinant factors continue to increase. On the basis of treatment type, the recombinant factors segment is expected to generate significant revenues, accounting for a value of over US$ 4,000 Mn by the end of 2022. On the other hand, the plasma derived factors treatment type segment is expected to register a robust CAGR throughout the forecast period. Based on age, the adults segment is expected to represent the highest growth in terms of revenue, recording a value of over US$ 3,000 Mn by the end 2017. However, the pediatric age segment is expected to represent the highest CAGR in the global market through 2022.

Competition Tracking

Leading market players operating in the global rare hematology market include Shire plc, Biogen Inc., Novo Nordisk A/S, Bayer Healthcare AG, CSL Behring LLC, Pfizer Inc., PRA Health Sciences, Celgene Corporation, Alexion Pharmaceuticals, Inc. and Amgen Inc.

Global Rare Hematology Market: Overview

The global rare hematology market is expected to witness a healthy growth attributed to growing prevalence of blood related disorders. Surge in demand to conduct the diagnosis process at the early phase is expected to impact growth of the global rare hematology market significantly. Moreover, increasing number of clinical trials to develop enhanced treatment process is further expected to encourage the progress of the global rare hematology market. With the growing demand for shorter diagnosis procedure, hematologists are increasingly focusing on enhancing their diagnosis skills.

The report offers an in-depth insight on some crucial aspects of the global rare hematology market and provides information on the growth patterns, factors fuelling the market growth, competitive landscape and important segments.

Global Rare Hematology Market: Dynamics

Growth of the global rare hematology market is mainly bound by various macro-economic and micro-economic factors. The report reveals that the global rare hematology market is mainly driven by the growing prevalence of various blood related disorders. As majority of the treatment procedures for the hematology diseases are not certified by the FDA, the hematologists are increasingly focusing on development new and safe drug products for enhanced treatment procedure. As hundreds of the clinical trials that are at the final stage are mainly stuck in the FDA pipeline for approval and evaluation, the global rare hematology market is expected to witness an inhibiting growth. Moreover, the researchers, patients, advocacy groups and caregivers are uniting to spread awareness about the blood disorders.

On the other hand, inadequate support by the disease-specific foundations for research is expected to restrain growth of the global rare hematology market. Moreover, the patients, advocacy groups, caregivers and patients are coming together in order to spread awareness. These factors are likely to contribute towards growth of the global market.

Global Rare Hematology Market: Segmentation

The global rare hematology market is mainly segmented into treatment type, age and region. On the basis of treatment type, the global market is segmented as plasma derived factors, recombinant factors, hemophilia A, hemophilia B, von wilebrand disease, acquired hemophilia A and others. Based on age, the global market is segmented as adult and pediatric. By regions, the global rare hematology market is segmented as North America, Latin America, Europe, Japan, APEJ and MEA.

Global Rare Hematology Market: Competition

Key players operating in the global market of rare hematology are Bayer Healthcare AG, Pfizer Inc., PRA Health Sciences, Alexion Pharmaceuticals, Inc., Shire plc, Pfizer Inc., Celgene Corporation, Amgen Inc., Biogen Inc., Novo Nordisk A/S, CSL Behring LLC and PRA Health Sciences.


 
 
Back To Top